Pekin Hardy Strauss Inc. Cuts Position in Sanofi (NASDAQ:SNY)

Pekin Hardy Strauss Inc. cut its stake in Sanofi (NASDAQ:SNY) by 6.3% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 10,018 shares of the company’s stock after selling 679 shares during the period. Pekin Hardy Strauss Inc.’s holdings in Sanofi were worth $486,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. TCTC Holdings LLC grew its position in Sanofi by 28.0% in the first quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock worth $47,000 after acquiring an additional 210 shares in the last quarter. HB Wealth Management LLC grew its position in Sanofi by 3.7% in the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock worth $299,000 after acquiring an additional 221 shares in the last quarter. Wynn Capital LLC grew its position in Sanofi by 4.5% in the first quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock worth $256,000 after acquiring an additional 226 shares in the last quarter. Angeles Investment Advisors LLC grew its position in Sanofi by 2.1% in the fourth quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company’s stock worth $598,000 after acquiring an additional 244 shares in the last quarter. Finally, EP Wealth Advisors LLC grew its position in Sanofi by 5.3% in the fourth quarter. EP Wealth Advisors LLC now owns 5,035 shares of the company’s stock worth $250,000 after acquiring an additional 255 shares in the last quarter. 10.04% of the stock is currently owned by hedge funds and other institutional investors.

Sanofi Stock Performance

Sanofi stock opened at $56.91 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The firm has a 50-day moving average of $53.95 and a 200-day moving average of $50.30. The firm has a market cap of $144.14 billion, a P/E ratio of 28.60, a P/E/G ratio of 1.60 and a beta of 0.60. Sanofi has a 1-year low of $42.63 and a 1-year high of $58.97.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.05. The company had revenue of $10.75 billion during the quarter, compared to analyst estimates of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. Sanofi’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.95 earnings per share. Sell-side analysts expect that Sanofi will post 4.25 EPS for the current year.

Wall Street Analysts Forecast Growth

SNY has been the subject of several analyst reports. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, September 11th. Argus upped their price target on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, Sanofi has a consensus rating of “Hold” and a consensus price target of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.